BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37247890)

  • 1. CDX2-positive Cancer of Unknown Primary With Upper-body Paralysis Was Dramatically Improved by Colorectal Cancer Chemotherapy.
    Akagi H; Tanaka Y; Wada K; Takahashi M; Yoshida K; Domoto H
    Anticancer Res; 2023 Jun; 43(6):2879-2884. PubMed ID: 37247890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer.
    Zhang BY; Jones JC; Briggler AM; Hubbard JM; Kipp BR; Sargent DJ; Dixon JG; Grothey A
    Clin Colorectal Cancer; 2017 Jun; 16(2):124-128. PubMed ID: 27726953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sidedness Matters: Surrogate Biomarkers Prognosticate Colorectal Cancer upon Anatomic Location.
    Ben-Aharon I; Goshen-Lago T; Sternschuss M; Morgenstern S; Geva R; Beny A; Dror Y; Steiner M; Hubert A; Idelevich E; Shulman K; Mishaeli M; Man S; Liebermann N; Soussan-Gutman L; Brenner B
    Oncologist; 2019 Aug; 24(8):e696-e701. PubMed ID: 30755502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous Metastasis of Transverse Colon Cancer with an Aberrant Pattern of CK7/CK20/CDX2 and High Microsatellite Instability.
    Omiya M; Murata T; Sawaki A; Teshima S; Kawachi J
    Intern Med; 2023 Dec; 62(24):3625-3630. PubMed ID: 37164671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of CDX2 and cytokeratins 7 and 20 expression in differentiating colorectal adenocarcinomas from extraintestinal gastrointestinal adenocarcinomas: cytokeratin 7-/20+ phenotype is more specific than CDX2 antibody.
    Bayrak R; Haltas H; Yenidunya S
    Diagn Pathol; 2012 Jan; 7():9. PubMed ID: 22268990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDX2 as a useful marker of colorectal adenocarcinoma metastases to lung in pre-operative biopsy specimens.
    Tanaka S; Saito K; Ito T; Tajima K; Mogi A; Shitara Y; Sano T; Kuwano H
    Oncol Rep; 2007 Jul; 18(1):87-92. PubMed ID: 17549351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX2.
    McCluggage WG; Shah R; Connolly LE; McBride HA
    Int J Gynecol Pathol; 2008 Jan; 27(1):92-100. PubMed ID: 18156982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying colorectal metastases in liver biopsies: the novel CDX2 antibody is less specific than the cytokeratin 20+/7- phenotype.
    Tot T
    Med Sci Monit; 2004 May; 10(5):BR139-43. PubMed ID: 15114262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDX2, cytokeratins 7 and 20 immunoreactivity in rectal adenocarcinoma.
    Saad RS; Silverman JF; Khalifa MA; Rowsell C
    Appl Immunohistochem Mol Morphol; 2009 May; 17(3):196-201. PubMed ID: 19098678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical expression of CK20, CK7, and CDX2 in colorectal carcinoma in correlation with pathomorphological characteristics.
    Ilieva N; Tashkova D; Staykov D; Serteva D; Feodorova Y; Mehterov N; Mollova A; Bachurska S
    Folia Med (Plovdiv); 2022 Apr; 64(2):214-220. PubMed ID: 35851772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CK7, CK20, CDX2 and MUC2 Immunohistochemical staining used to distinguish metastatic colorectal carcinoma involving ovary from primary ovarian mucinous adenocarcinoma.
    Shin JH; Bae JH; Lee A; Jung CK; Yim HW; Park JS; Lee KY
    Jpn J Clin Oncol; 2010 Mar; 40(3):208-13. PubMed ID: 19926591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of CDX2 immunoexpression in poorly differentiated clusters of colorectal carcinoma.
    Reggiani Bonetti L; Lionti S; Vitarelli E; Barresi V
    Virchows Arch; 2017 Dec; 471(6):731-741. PubMed ID: 28819729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential diagnostic and functional role of the multi-marker phenotype CDX2/CK20/CK7 in colorectal cancer stratified by mismatch repair status.
    Lugli A; Tzankov A; Zlobec I; Terracciano LM
    Mod Pathol; 2008 Nov; 21(11):1403-12. PubMed ID: 18587323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of CDX2/CK20 expression is associated with poorly differentiated carcinoma, the CpG island methylator phenotype, and adverse prognosis in microsatellite-unstable colorectal cancer.
    Kim JH; Rhee YY; Bae JM; Cho NY; Kang GH
    Am J Surg Pathol; 2013 Oct; 37(10):1532-41. PubMed ID: 24025523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of CDX-2 and Ki-67 in different grades of colorectal adenocarcinomas.
    Sen A; Mitra S; Das RN; Dasgupta S; Saha K; Chatterjee U; Mukherjee K; Datta C; Chattopadhyay BK
    Indian J Pathol Microbiol; 2015; 58(2):158-62. PubMed ID: 25885126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia-inducible factor-1alpha modulates the down-regulation of the homeodomain protein CDX2 in colorectal cancer.
    Zheng J; Sun X; Wang W; Lu S
    Oncol Rep; 2010 Jul; 24(1):97-104. PubMed ID: 20514449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic impact of CDX2 correlates with the underlying mismatch repair status and BRAF mutational status but not with distant metastasis in colorectal cancer.
    Neumann J; Heinemann V; Engel J; Kirchner T; Stintzing S
    Virchows Arch; 2018 Aug; 473(2):199-207. PubMed ID: 29675807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [CK7, CK20, SOX10 and CDX2: expressions and diagnostic values in primary adenocarcinoma of the sinonasal tract].
    Yue C; Piao Y; Bai Y; Liu H; Zhang L
    Zhonghua Yi Xue Za Zhi; 2015 Aug; 95(30):2447-50. PubMed ID: 26711206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma.
    Park SY; Kim BH; Kim JH; Lee S; Kang GH
    Arch Pathol Lab Med; 2007 Oct; 131(10):1561-7. PubMed ID: 17922593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDX2 Is a Prognostic Biomarker for Unresectable Metastatic Colorectal Cancer.
    Mukohyama J; Agawa K; Yamashita K; Matsuda T; Shinoda M; Itano O; Kakeji Y
    Anticancer Res; 2023 Aug; 43(8):3763-3767. PubMed ID: 37500172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.